Coagulation factors and plasma proteins at the biomaterial surface

The interaction of coagulation factors and plasma proteins at a biomaterial surface describes the complex physiological response that occurs when blood contacts non-biological materials, such as stents, catheters, or dialysis membranes. Upon contact, a rapid sequence of protein adsorption occurs—often referred to as the Vroman effect—where abundant proteins like albumin are gradually replaced by proteins with higher surface affinity, such as fibrinogen and Factor XII (Hageman factor) (Vroman, 1962; Wilson et al., 2005). This adsorption often triggers the contact activation (intrinsic) pathway of coagulation and the complement system, leading to the formation of a thrombus and the initiation of a foreign body inflammatory response (Gorbet & Sefton, 2004). In clinical practice, this 'target' is managed not as a single molecule but as a system-wide challenge in biocompatibility. Therapeutic intervention involves the use of systemic anticoagulants like heparin or direct thrombin inhibitors to prevent clot formation, or the engineering of 'stealth' surfaces that minimize protein adhesion (Ratner, 2013). Failure to control these interactions can lead to serious complications, including device failure, embolic stroke, or systemic inflammatory distress. Consequently, understanding the molecular behavior of these proteins at the interface is vital for the design of next-generation medical implants and extracorporeal circuits (Schmaier, 2008).

Other names

Blood-biomaterial interface proteinsContact activation systemVroman effect proteinsSurface-adsorbed plasma proteinsProtein corona

Drugs typically target specific components within this group, such as Factor Xa or Thrombin, to inhibit the coagulation cascade initiated by surface contact. Surface modifications of biomaterials (e.g., heparin coating) aim to prevent the initial adsorption and activation of these proteins.